tirzepatide birth defects | C225H348N48O68 | CID 156588324 How GLP-1 weight-loss drugs can

A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug

doi: 10.1038/s41467-024-55219-5 8

Blurred eyesight is a relatively common side effect, but you should still tell your doctor if you experience it

Contact your healthcare provider immediately if you experience blood in stool, severe persistent abdominal pain, high fever with gastrointestinal symptoms, signs of dehydration, or persistent vomiting

Your provider will review your test trends and may order additional imaging or specialist consultation if enzyme patterns concern them